01:30 AM EDT, 10/15/2026 (MT Newswires) -- Kuros Biosciences (KURN.SW) raised its group sales growth guidance for full-year 2026, according to a Thursday filing. The bone healing technologies company now expects group sales to rise 36% to 40% annually, compared with the August forecast of at least a 35% jump. For the nine months ended Sept. 30, the company reported total medical device sales of $141.8 million, compared with $101.1 million a year ago.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.